AIVITA Biomedical

AIVITA Biomedical is a private, clinical-stage biotech leveraging its proprietary stem cell and autologous immunotherapy platform to develop personalized vaccines. Its lead oncology programs target glioblastoma and melanoma, with a Phase 2/3 trial planned for glioblastoma and a Phase 1B trial ongoing in melanoma. The company has also developed a multi-pathogen vaccine kit and funds its R&D in part through a clinically validated skincare product line.

Proprietary autologous dendritic cell vaccine platform. Utilizes patient-specific dendritic cells loaded with either autologous tumor-initiating cells (for a pan-antigenic cancer vaccine) or multiple pathogen antigens (for a broad-spectrum preventative vaccine). Built on foundational proprietary stem cell media and manufacturing methods.

In personalized cancer vaccines, AIVITA competes with companies like BioNTech, Moderna (mRNA neoantigen vaccines), and other dendritic cell therapy developers. Its pan-antigenic approach via whole tumor-initiating cells is a key differentiator. In multi-pathogen prevention, it faces competition from all major vaccine manufacturers, though its combination-kit approach is novel.